Beata Matejczyk-Mackowiak
Bialystok, PD 15027, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature.
Journal: Antibodies (Basel, Switzerland)
Published: March 26, 2026
Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab.
Journal: Cancers
Published: January 19, 2026
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 28, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 25, 2024
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 27, 2024
Survival with Cemiplimab in Recurrent Cervical Cancer.
Journal: The New England journal of medicine
Published: February 09, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 01, 2021
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 06, 2018
Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Journal: Journal of ovarian research
Published: May 23, 2016
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.
Journal: Advances in medical sciences
Published: May 07, 2015
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: November 17, 2014
Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Journal: European cytokine network
Published: November 08, 2013
Last Updated: 09/26/2026